Paroxysmal Nocturnal Hemoglobinuria (PNH)
Institution
Arkansas Children’s Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
Nutrition and Bone Marrow Failure
Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Bone Marrow Transplant
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric Bone Marrow Failure Diseases
Related Bone Marrow Failure Diseases and Malignancies
In this webinar, Doris Piccinin, registered dietician, will discuss how diet can play a role in living well with a bone marrow failure disease. You can submit questions in advance by emailing help@aamds.org.
Ashwin Kishtagari, MD
Institution
Vanderbilt University Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
David Hermel, MD
Institution
Scripps Clinic
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
David Hermel, MD, is a hematologist and medical oncologist who specializes in malignant hematology with an interest in the use of novel therapies, such as cellular immunotherapy and bone marrow transplantation, for the treatment of blood and immune system disorders. As a member of the Scripps Blood and Marrow Transplant Program, he works with a multi-disciplinary team of professionals to provide hematopoietic stem cell transplantation to his patients. Dr. Hermel’s clinical practice is focused on the treatment of blood cancers, such as acute and chronic leukemias, multiple myeloma, Hodgkin’s
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria paroxysmal noctur
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Pegcetacoplan Pegcetacoplan: EMPAVELI® is the first PNH treatment that binds to complement protein C3.
Blood Transfusions and Iron Overload
Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
In this webinar, Dr. Thomas Coates will discuss blood transfusions and the potential side effect, iron overload. You may submit questions in advance by emailing help@aamds.org.
Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
Patients with paroxysmal nocturnal hemoglobinuria paroxysmal nocturnal hemoglobinuria:
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Introduction: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal he
